{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Pandey MK"],"pubmed_abstract":["Due to the advent of various biologics like antibodies, proteins, cells, viruses, and extracellular vesicles as biomarkers for disease diagnosis, progression, and as therapeutics, there exists a need to have a simple and ready to use radiolabeling synthon to enable noninvasive imaging trafficking studies. Previously, we reported [<sup>89</sup>Zr]zirconium-<i>p</i>-isothiocyanatobenzyl-desferrioxamine ([<sup>89</sup>Zr]Zr-DBN) as a synthon for the radiolabeling of biologics to allow PET imaging of cell trafficking. In this study, we focused on improving the molar activity (A<sub>m</sub>) of [<sup>89</sup>Zr]Zr-DBN, by enhancing <sup>89</sup>Zr production on a low-energy cyclotron and developing a new reverse phase HPLC method to purify [<sup>89</sup>Zr]Zr-DBN. To enhance <sup>89</sup>Zr production, a new solid target was designed, and production yield was optimized by varying, thickness of yttrium foil, beam current, irradiation duration and proton beam energy. After optimization, 4.78±0.33 GBq (129.3±8.9 mCi) of <sup>89</sup>Zr was produced at 40 µA for 180 min (3 h) proton irradiation decay corrected to the end of bombardment with a saturation yield of 4.56±0.31 MBq/µA. Additionally, after reverse phase HPLC purification the molar activity of [<sup>89</sup>Zr]Zr-DBN was found to be in 165-316 GBq/µmol range. The high molar activity of [<sup>89</sup>Zr]Zr-DBN also allowed radiolabeling of low concentration of proteins in relatively higher yield. The stability of [<sup>89</sup>Zr]Zr-DBN was measured over time with and without the presence of ascorbic acid. The newly designed solid target assembly and HPLC method of [<sup>89</sup>Zr]Zr-DBN purification can be adopted in the routine production of <sup>89</sup>Zr and [<sup>89</sup>Zr]Zr-DBN, respectively."],"journal":["American journal of nuclear medicine and molecular imaging"],"pagination":["15-24"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8918403"],"repository":["biostudies-literature"],"pubmed_title":["A new solid target design for the production of <sup>89</sup>Zr and radiosynthesis of high molar activity [<sup>89</sup>Zr]Zr-DBN."],"pmcid":["PMC8918403"],"pubmed_authors":["Bansal A","Berg HM","Ellinghuysen JR","DeGrado TR","Pandey MK","Vail DJ"],"additional_accession":[]},"is_claimable":false,"name":"A new solid target design for the production of <sup>89</sup>Zr and radiosynthesis of high molar activity [<sup>89</sup>Zr]Zr-DBN.","description":"Due to the advent of various biologics like antibodies, proteins, cells, viruses, and extracellular vesicles as biomarkers for disease diagnosis, progression, and as therapeutics, there exists a need to have a simple and ready to use radiolabeling synthon to enable noninvasive imaging trafficking studies. Previously, we reported [<sup>89</sup>Zr]zirconium-<i>p</i>-isothiocyanatobenzyl-desferrioxamine ([<sup>89</sup>Zr]Zr-DBN) as a synthon for the radiolabeling of biologics to allow PET imaging of cell trafficking. In this study, we focused on improving the molar activity (A<sub>m</sub>) of [<sup>89</sup>Zr]Zr-DBN, by enhancing <sup>89</sup>Zr production on a low-energy cyclotron and developing a new reverse phase HPLC method to purify [<sup>89</sup>Zr]Zr-DBN. To enhance <sup>89</sup>Zr production, a new solid target was designed, and production yield was optimized by varying, thickness of yttrium foil, beam current, irradiation duration and proton beam energy. After optimization, 4.78±0.33 GBq (129.3±8.9 mCi) of <sup>89</sup>Zr was produced at 40 µA for 180 min (3 h) proton irradiation decay corrected to the end of bombardment with a saturation yield of 4.56±0.31 MBq/µA. Additionally, after reverse phase HPLC purification the molar activity of [<sup>89</sup>Zr]Zr-DBN was found to be in 165-316 GBq/µmol range. The high molar activity of [<sup>89</sup>Zr]Zr-DBN also allowed radiolabeling of low concentration of proteins in relatively higher yield. The stability of [<sup>89</sup>Zr]Zr-DBN was measured over time with and without the presence of ascorbic acid. The newly designed solid target assembly and HPLC method of [<sup>89</sup>Zr]Zr-DBN purification can be adopted in the routine production of <sup>89</sup>Zr and [<sup>89</sup>Zr]Zr-DBN, respectively.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T23:33:54.94Z","creation":"2025-04-04T23:33:54.94Z"},"accession":"S-EPMC8918403","cross_references":{"pubmed":["35295887"]}}